Galapagos, having backtracked on split, weighs sale of cell therapy business

A decision to possibly sell the business, which was poised to become the centerpiece of a restructuring plan, represents a shift in strategy by new company leaders.

By Kristin Jensen • July 24, 2025

Rocket lays off staff; Abivax capitalizes on immune drug data

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck research deals.

By BioPharma Dive staff • July 24, 2025

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

Abivax stock soars on trial data for ulcerative colitis drug

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

By Kristin Jensen • July 23, 2025

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.

By Ben Fidler • July 23, 2025

Sanofi to acquire vaccine biotech in billion-dollar deal

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV and metapneumovirus.

By Delilah Alvarado • Updated July 22, 2025

Replimune drug rejected by FDA; Omega raises $647M biotech fund

Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at the FDA.

By BioPharma Dive staff • July 22, 2025

Apples to apples: Stelara biosimilars and the fight for market share

How will payers determine which Stelara biosimilar to add to their formularies?

By Samantha Ngan, Associate Manager, Market Research, MMIT and Andrew Rouff, Senior Consultant, Advisory Services, MMIT • July 21, 2025

Bristol Myers’ Reblozyl falls short in Phase 3; Blenrep voted down by FDA panel

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have become more difficult after the negative advisory committee vote.

By BioPharma Dive staff • July 18, 2025

Sarepta reports patient death in limb-girdle trial, compounding concerns on gene therapy risks

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed gene therapy Elevidys.

By Ben Fidler • Updated July 18, 2025

Biotech startup funding dried up in second quarter, HSBC finds

Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast start, according to HSBC.

By Gwendolyn Wu • July 17, 2025

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was essential to ensuring Sarepta's "long-term viability."

By Ben Fidler • Updated July 16, 2025

Hengrui, Kailera say dual-acting obesity shot succeeds in China study

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to begin global late-stage testing.

By Ben Fidler • July 15, 2025

Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.

By BioPharma Dive staff • July 15, 2025

FDA rejects Ultragenyx gene therapy over manufacturing concerns

While the CRL derails a near-term clearance, one analyst described the rejection as more of “a speed bump to approval, rather than a roadblock.”

By Delilah Alvarado • July 14, 2025

Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update

Current operations chief Renee Gala will succeed Bruce Cozadd at Jazz. Meanwhile, Nuclidium raised about $99 million to develop radiopharmaceuticals that involve copper isotopes.

By BioPharma Dive staff • July 11, 2025

Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding

The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.

By Gwendolyn Wu • July 10, 2025

Gilead signs lenacapavir access deal; Arvinas CEO to step down

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.

By BioPharma Dive staff • July 9, 2025

Actithera draws new investors to radiopharma drug pitch

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

By Gwendolyn Wu • July 9, 2025

Cargo agrees to Concentra buyout after trial setback, layoffs

The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a safety setback forced it to scrap its lead candidate.

By Ned Pagliarulo • July 8, 2025

Protein degraders: chasing undruggable targets

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over the past two decades.

By Gwendolyn Wu • Updated July 9, 2025

After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an on-time approval.

By Jonathan Gardner • July 7, 2025

Study results boost Cogent’s case for rare disease drug

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a competitor to Blueprint Medicines’ Ayvakit.

By Gwendolyn Wu • July 7, 2025

[Podcast] Trial Trailblazers: Behind clinical breakthroughs

Explore how innovative clinical trials are transforming treatments for children with rare diseases in this compelling podcast.

By BioPharma Dive's studioID • July 7, 2025

Regeneron bispecific approved for myeloma; Concentra to buy IGM

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

By BioPharma Dive staff • July 2, 2025

Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.”

By Jacob Bell • July 2, 2025